Nurix.png
Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting
20 mars 2024 09h40 HE | Nurix Therapeutics, Inc.
Disclosure of the discovery and structure of NX-1607, the first inhibitor of CBL-B to advance into clinical studies.